Tumor-associated neutrophils promote breast cancer progression via RLN2/RXFP1-C6orf99-STAT3 axis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Tumor-associated neutrophils (TANs) drive breast cancer progression by downregulating the protective C6orf99 long non-coding RNA. This pathway, involving RLN2/RXFP1 and STAT3, offers new therapeutic targets for breast cancer treatment.
Area Of Science
- Oncology
- Immunology
- Molecular Biology
Background
- Tumor-associated neutrophils (TANs) are key players in breast cancer progression.
- High TANs infiltration correlates with poor disease-free survival (DFS) and enhanced cancer cell proliferation, migration, and invasion.
- The long non-coding RNA C6orf99 is downregulated in breast cancer and linked to favorable DFS.
Purpose Of The Study
- To investigate the role of TANs in breast cancer progression.
- To elucidate the molecular mechanisms underlying TANs-mediated breast cancer development.
- To identify potential therapeutic targets within the TANs-C6orf99 signaling axis.
Main Methods
- Analysis of CD66b+ TANs infiltration and its correlation with DFS.
- In vitro functional assays to assess the impact of C6orf99 on cancer cell behavior.
- Investigation of the RLN2/RXFP1-C6orf99-STAT3 signaling pathway.
- Clinical correlation studies of C6orf99 expression, TANs density, and phospho-STAT3 levels in patient tissues.
Main Results
- High CD66b+ TANs infiltration was associated with poor DFS and promoted breast cancer cell proliferation, migration, and invasion.
- C6orf99 suppressed tumor growth and metastasis by inhibiting STAT3 phosphorylation.
- TANs-derived RLN2 downregulated C6orf99 via RXFP1, leading to STAT3 phosphorylation.
- C6orf99 expression inversely correlated with TANs density and phospho-STAT3 levels in breast cancer tissues.
Conclusions
- TANs critically regulate breast cancer progression through the RLN2/RXFP1-C6orf99-STAT3 axis.
- Targeting this axis presents a potential therapeutic strategy for breast cancer.
- C6orf99 serves as a potential biomarker and therapeutic target in breast cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...